:: Worldwide Markets for Blood Disorder Treatments (PHM039A) ::

Pharmaceuticals

Worldwide Markets for Blood Disorder Treatments

Report Code: PHM039A, Published: June 2004

Click here for an updated version: PHM039B

REPORT HIGHLIGHTS

For 2003, the total worldwide market for blood disorder treatments was estimated at $25.4 billion. Rising at an average annual growth rate (AAGR) of 6.7%, the market is expected to exceed $35 billion by 2008.
The prescription anemia pharmaceutical treatment segment accounts for the largest portion of revenues, with $10 billion in 2003 but is growing at a slower pace than the overall market, at 5.9%.
Prescription thrombosis treatments, the second largest segment, will account for about $12.3 billion in 2008, up from $9.2 billion in 2003.
Rising the fastest are treatments for neutropenia at an AAGR of 9%, and will reach nearly $4.6 billion in 2008.

Report Code: PHM039A, Published: June 2004, Analyst: Mary Anne Crandall

INTRODUCTION

The blood disorder treatment market is growing rapidly due to recent advancements in pharmaceutical products, advancements in delivery of medications and increasingly accurate diagnoses. Emphasis has been placed on early detection and treatment of disorders and new products that are on the horizon.

Biotechnology products have had a significant impact on overall patient morbidity and mortality. There are several products on the market for treating various blood disorders and diseases, and many more are in clinical trials. These products are expected to greatly impact the market, pushing revenues higher and fueling the demand for innovative treatments for blood disorders.

This timely BCC report details the market for blood disorder treatments. Several key issues are discussed in detail including the great need to educate patients and others about blood clots. The impact of thrombosis is underestimated. More than five million individuals are affected each year and it is the third most common cardiovascular event worldwide. Deep vein thrombosis (DVT) and pulmonary embolism (PE) account for more than 250,000 hospitalizations in the United States each year. DVT and PE can be silent killers, because patients do not always present with typical signs and symptoms. That makes the detection of DVT and PE much more difficult. Education seems to be the key to addressing this need.

SCOPE OF STUDY

The report contains:

Identification of the different products used to treat various blood disorders
Details on the blood disorder market size and its participants
Discussion of products in research and development
Details of the industry, its relationship to the health-care industry, its economic consequences and its participants
Market forecasts through 2008 for the following product segments: anemia, hemophilia, neutropenia and thrombosis.

METHODOLOGY AND INFORMATION SOURCES

The information and analysis presented in this BCC, Inc. report are based on extensive first-hand interviews with primary executives, product managers, and clinical specialists in the area of blood disorders. Background information was obtained from various government, , medical journal, hematology journal and trade magazines, and interviews with hematologists, physicians, and nurses involved in hematological conditions. Key information from published literature was used to conduct interviews with industry participants to validate and obtain expert opinions on current and future trends in the area of blood disorders. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as formulating market projections.

All market data pertain to revenues at the manufacturer's level. Data are expressed in current U.S. dollars. The based year was 2003. Historical data is provided for 2001 and 2002, and forecast data is provided for 2008. Historical, based year and forecast data is provided for each market segment and subsegment. Market shares are provided for each market segment for the 2003 base year.

ANALYST CREDENTIALS

Mary Anne Crandall has been publishing market research in the life sciences for more than 17 years. She holds a Master of Science Degree in psychology, and is the founder and CEO of Mountaintop Medical, LLC, a consulting firm in Oregon. She has taught at Southern Oregon University for more than 16 years, and before joining BCC's analytical team, she published with Frost & Sullivan, Theta Reports, FIND/SVP, MDI, FeedBack Research Services, Prognosis and Hall Enterprises. Ms. Crandall specializes in prescription pharmaceutical markets.

Report Code: PHM039A, Published: June 2004, Analyst: Mary Anne Crandall

Visit the Table of Contents to purchase the report or to download the introduction chapter for free.